nordisk semaglutide Novo medicines containing Type 2 diabetes: New Ozempic

In SURMOUNT-2, SURMOUNT-3 and SURMOUNT-4 were used TZP doses of 10 and 15 mg and all three doses, including the 5-mg dose, were used in SURMOUNT-1

Energy, mood, and metabolic-related processes

In STEP 1-3 clinical trials, a weekly dose of 2.4 mg semaglutide resulted in a 49% reduction in C-reactive protein (CRP) levels, while a 1 mg weekly dose led to a 42% decrease, compared to placebo after 68 weeks

GLP-1 Discontinuation Rates in Type 2 Diabetes "Using insurance records from more than 60,000 Americans with type 2 diabetes, we found that about 4 in 10 patients stopped their GLP-1 medication within the first year, and nearly 6 in 10 had stopped by the end of two years," Sontha said

We strongly advise you to talk with a health care professional about specific medical conditions and treatments